EXTL2P1: A Drug Target / Disease Biomarker (G100287682)

Target Name: EXTL2P1

NCBI ID: G100287682

EXTL2P1

Other Name(s): EXTL2P | exostosin like glycosyltransferase 2 pseudogene 1 | Exostosin like glycosyltransferase 2 pseudogene 1 | Exostoses (multiple)-like 2 pseudogene 1

EXTL2P1: A Drug Target / Disease Biomarker

EXTL2P1, also known as EXTL2-p1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the extracellular matrix (ECM) protein family, which plays a crucial role in the structure and function of tissues and organs. EXTL2P1 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The EXTL2P1 protein is composed of 254 amino acid residues and has a calculated molecular weight of 31.1 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, kidney, and pancreas. It is highly expressed in the brain, with higher levels of expression observed in the prefrontal cortex and the hippocampus compared to other regions of the brain.

EXTL2P1 is involved in several cellular processes that are important for tissue development, maintenance, and repair. It is a structural component of the cytoskeleton and is involved in the organization and stability of various cellular structures. It also plays a role in cell adhesion, as it is involved in the interaction between cells and extracellular matrix (ECM) components.

In addition to its role in cellular structure and organization, EXTL2P1 is also involved in several signaling pathways that are important for cellular function. It is a negative regulator of the TGF-β pathway, a pathway that is involved in cell growth, differentiation, and survival. EXTL2P1 has been shown to inhibit the activity of the TGF-β pathway, which is important for the development and maintenance of tissues and organs.

EXTL2P1 has also been shown to be involved in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroinclusions. EXTL2P1 has been shown to be involved in the development and progression of these conditions, as it has been shown to promote the formation of neurofibrillary tangles and neuroinclusions in animal models of these diseases.

In addition to its involvement in neurodegenerative diseases, EXTL2P1 has also been identified as a potential drug target for several other conditions, including cancer and autoimmune disorders. For example, EXTL2P1 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

Given its involvement in several cellular processes and its potential as a drug target, EXTL2P1 is an attractive target for researchers to investigate and develop new treatments for a variety of diseases. Researchers are currently working to identify small molecules that can inhibit the activity of EXTL2P1 and to determine its potential as a drug. These studies are being conducted in a variety of cellular models, including cell lines and animal models, to determine the effectiveness of these treatments.

In conclusion, EXTL2P1 is a protein that is involved in several cellular processes that are important for tissue development, maintenance, and repair. It is a structural component of the cytoskeleton and is involved in cell adhesion, as well as several signaling pathways that are important for cellular function. EXTL2P1 has been identified as a potential drug target and biomarker for several diseases, including cancer and neurodegenerative disorders. Further research is needed to determine its full potential as a drug and to develop new treatments for a variety of conditions.

Protein Name: Exostosin Like Glycosyltransferase 2 Pseudogene 1

The "EXTL2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXTL2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets